0.6331
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D. - ACCESS Newswire
Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder - ACCESS Newswire
Alcohol Use Disorder Treatment Market: Discover the Best - openPR.com
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 19.8% in March - Defense World
Adial Pharmaceuticals Appoints Tony Goodman as COO - TipRanks
Adial Pharmaceuticals appoints new COO Tony Goodman - Investing.com
Litchfield Hills Research Predicts ADIL Q1 Earnings - Defense World
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Grows By 610.2% - Defense World
Adial Pharma stock hits 52-week low at $0.69 amid market challenges - Investing.com
Brookline Capital Management Estimates ADIL Q1 Earnings - Defense World
Rodman & Renshaw maintains Adial stock Buy rating, $8 target By Investing.com - Investing.com Australia
Rodman & Renshaw maintains Adial stock Buy rating, $8 target - Investing.com India
Adial Pharma stock hits 52-week low at $0.71 amid market challenges - Investing.com
Adial Pharma stock hits 52-week low at $0.71 amid market challenges By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - GlobeNewswire
ADIAL PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Adial Pharmaceuticals expects cash to fund operations into 2H of 2025 - TipRanks
Can Adial's FDA-Approved Strategy for Alcohol Treatment Offset Its Widening Losses? - StockTitan
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial - ACCESS Newswire
Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA - ACCESS Newswire
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits - ACCESS Newswire
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia - accessnewswire.com
Adial Pharmaceuticals Receives Positive FDA Feedback on In Vitro Bridging Strategy for AD04 - Defense World
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland - ACCESS Newswire
Adial gets FDA nod for Phase 3 drug strategy By Investing.com - Investing.com Australia
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs - AOL.com
Adial gets FDA nod for Phase 3 drug strategy - Investing.com India
Adial Pharmaceuticals Receives Positive Response from FDA - GlobeNewswire
Adial Pharmaceuticals Receives FDA's Positive Feedback On AD04 In Vitro Bridging Strategy - Nasdaq
Adial Pharmaceuticals Advances AD04 with FDA Approval - TipRanks
Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - StockTitan
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder - Benzinga
Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City - ACCESS Newswire
Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare - ACCESS Newswire
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia - ACCESS Newswire
Adial Pharmaceuticals secures patent for genetic addiction treatment By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Granted New U.S. Patent Expanding - GlobeNewswire
Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders - Marketscreener.com
Adial Granted New U.S. Patent Expanding Genetic-Based Approach For Addiction Treatment - Nasdaq
Adial Pharmaceuticals secures patent for genetic addiction treatment - Investing.com
This Groundbreaking Patent Could Transform How We Treat AddictionHere's Why Genetics Matter - StockTitan
Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria - ACCESS Newswire
Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug - Citeline News & Insights
Adial Pharmaceuticals secures new patent for addiction treatment By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short Interest - Defense World
Adial Pharmaceuticals secures new patent for addiction treatment - Investing.com India
Adial Pharmaceuticals Awarded U.S. Patent For Genotype-Specific Treatment Of Opioid Disorders - Nasdaq
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - The Manila Times
Adial Pharmaceuticals Secures Patent for Genetically Targeted Treatment Methods in Addiction Therapy - Nasdaq
Revolutionary Patent Win: Adial's DNA-Guided Solution Takes On $35B Addiction Crisis - StockTitan
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Yahoo Finance
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):